Risk factors and impact of danshen compound dripping pill on aspirin resistance in patients with stable angina pectoris

AIM To assess the related risk factors for aspirin resistance (AR) in patients with stable angina pectoris (SAP) and to evaluate the impact of danshen compound dripping pill on AR. METHODSOne hundred and seventy-six SAP patients (65.9±7.4 years) who received daily aspirin therapy (≥100 mg) during 1 month were recruited. Effect of aspirin was assessed using thrombelastography (TEG) platelet mapping assay. Patients with AR (defined as platelet aggregation rate induced by AA≥50%) were randomly assigned to control group (n=36) treated with aspirin alone and observation group (n=36) treated with a combination of aspirin and danshen compund dripping pill. AA-induced platelet aggregation rates were measured 1 month after treatment and results were compared. RESULTSSeventy-two patients (19.1%) were aspirin resistant. Multivariate logistic regression analysis revealed that elevated fasting serum glucose level, C-reactive protein and low-density lipoprotein cholesterol were risk factors for AR as determined by TEG. In observation group, AA-induced platelet aggregation rate was significantly lower after 1 month treatment compared with that before treatment. CONCLUSIONA significant number of SAP patients are aspirin resistant. Fasting blood glucose level, C-reactive protein and low-density lipoprotein cholesterol are closely associated with AR in SAP patients. Danshen compound dripping pill has some anti-platelet effect in SAP patients with AR.